Ventyx Biosciences (NASDAQ: VTYX)

Some price data may be temporarily unavailable.

KEY DATA POINTS

Current Price

N/A

Daily Change

N/A

Day's Range

N/A

Previous Close

N/A

Open

N/A

Beta

N/A

Volume

N/A

Average Volume

N/A

Sector

Health Care

Market Cap

N/A

Market Cap / Employee

N/A

52wk Range

N/A

Revenue

N/A

Gross Margin

N/A

Dividend Yield

N/A

EPS

N/A

CAPs Rating

N/A

Industry

Pharmaceuticals

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Ventyx Biosciences Company Info

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded on November 21, 2018 and is headquartered in Encinitas, CA.